The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy

Journal:
Blood
Published:
Affiliations:
20
Authors:
22
Institutions Authors Share
Gilead, United States of America (USA)
5.000000
0.23
The University of Texas MD Anderson Cancer Center, United States of America (USA)
1.000000
0.05
University Medical Center Groningen (UMCG), RUG, Netherlands
1.000000
0.05
Ulm University Medical Center, Germany
1.000000
0.05
CHU Henri-Mondor, France
1.000000
0.05
University Hospital Královské Vinohrady, Czech Republic
1.000000
0.05
Sant'Orsola Malpighi Hospital, Italy
1.000000
0.05
La Fe University Hospital, Spain
1.000000
0.05
Rhode Island Hospital, United States of America (USA)
1.000000
0.05
Hôpital Saint-Louis, France
1.000000
0.05
Hospital Clinic of Barcelona, Spain
1.000000
0.05
National Taiwan University Hospital (NTUH), Taiwan
1.000000
0.05
University Hospital of Liege, Belgium
1.000000
0.05
University Hospital Brno, Czech Republic
1.000000
0.05
Erasmus MC Cancer Institute, Netherlands
1.000000
0.05
Medical College of Wisconsin (MCW), United States of America (USA)
1.000000
0.05
Oxford MRC Weatherall Institute of Molecular Medicine (WIMM), United Kingdom (UK)
0.500000
0.02
Oxford University Hospitals NHS Trust (OUH), United Kingdom (UK)
0.500000
0.02
European University of Madrid (UEM), Spain
0.500000
0.02
Hospital Universitario Quirónsalud Madrid, Spain
0.500000
0.02